Christian Rolfo, Director of the Division of Medical Oncology and Associate Director of Early Phase Clinical Trials at James Comprehensive Cancer Center, shared a post on X:
“Our paper in Clinical Cancer Research is out “Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC : Analyses from the Phase II VISION trial of Tepotinib”Analyses from the Phase II VISION trial of Tepotinib” important liquid biopsy application.”
More posts featuring Christian Rolfo on OncoDaily.